Pancreatic tumors carry the highest incidence of a KRAS mutation at approximately 70–90% [60], and reciprocally activated RAS/MEK pathways have conferred therapeutic resistance in pancreatic ductal adenocarcinoma. This evidence concerns the gene MAP2K7 and pancreatic ductal adenocarcinoma.